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ABSTRACT 24 
Surotomycin (CB-183,315), a cyclic lipopeptide is in phase 3 clinical development for 25 
the treatment of Clostridium difficile infection.  We report further characterization of the 26 
in vitro mode of action of surotomycin, including its activity against growing and non-27 
growing C. difficile.  This was assessed through time kill kinetics, determining effects on 28 
the membrane potential and permeability and macromolecular synthesis in C. difficile.  29 
Against representative strains of C. difficile, surotomycin displayed concentration-30 
dependent killing of both logarithmic-phase and stationary-phase cultures at a 31 
concentration that was ≤16-fold more than the minimum inhibitory concentration (MIC). 32 
Exposure resulted in the inhibition of macromolecular synthesis (DNA, RNA, protein and 33 
cell wall).  At bactericidal concentrations, surotomycin dissipated the membrane potential 34 
of C. difficile without changes to the permeability of propidium iodide.  These 35 
observations are consistent with surotomycin acting as a membrane-active antibiotic, 36 
exhibiting rapid bactericidal activities against growing and non-growing C. difficile. 37 
 38 
  39 
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INTRODUCTION 40 
The Gram-positive, spore-forming anaerobic bacterium Clostridium difficile is the 41 
leading cause of hospital-acquired diarrhea in North America and Europe (1, 2). Elderly 42 
hospitalized patients on broad-spectrum antibiotics are the main target populations, but 43 
recent observations indicate there is an increase in the incidence of C. difficile infection 44 
(CDI) in the community without known risk factors (3, 4).  In the United States in 2011 45 
there were an estimated 500,000 cases of CDI resulting in 29,300 deaths (5), reflecting 46 
the devastating impact of CDI since the turn of the last century.  Furthermore, the number 47 
of cases of severe CDI has escalated, coinciding with the emergence of epidemic 48 
ribotypes such as BI/NAP1/027 (2, 6). BI/NAP1/027 is now responsible for a significant 49 
number of cases of hospital-acquired CDI in North America (5, 6).  50 
For more than 30 years vancomycin and metronidazole have been the first-line 51 
treatment choices for CDI (7).  Metronidazole is prescribed for mild to moderate CDI, 52 
while vancomycin is recommended for severe CDI (6, 8). However, rates of recurrence of 53 
20-25% or higher in severe CDI are common, following treatment with metronidazole or 54 
vancomycin (6, 9, 10). The mode of action of vancomycin is well established, involving 55 
inhibition of the latter stages of peptidoglycan biosynthesis, which primarily kills rapidly 56 
growing C. difficile (11). Metronidazole undergoes biochemical reduction to form 57 
reactive species that target DNA and is potent in vitro, but only low concentrations reside 58 
in the gastrointestinal tract (12-16). Fidaxomicin, which targets the bacterial RNA 59 
polymerase inhibitor, has a narrower spectrum of activity than metronidazole and 60 
vancomycin and is superior in the prevention of CDI recurrence (17, 18). However, 61 
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additional novel therapeutics are required to effectively treat CDI and reduce the rates of 62 
recurrence following initial therapy.  63 
 Surotomycin is a minimally absorbed narrow-spectrum cyclic lipopeptide 64 
antibiotic, which is in phase 3 clinical trials as a novel treatment for CDI. It is chemically 65 
and structurally related to the antibiotic daptomycin that targets the bacterial membrane 66 
thereby exhibiting bactericidal effects (19-21). Daptomycin has been shown to display 67 
activities against stationary phase Staphylococcus aureus (21), which is a property that 68 
would seem amenable to the action of surotomycin in mitigating the pathogenesis of C. 69 
difficile.  This organism produces spores and toxin (TcdA and TcdB), primarily in the late 70 
logarithmic and stationary phases of growth (22). However, it is unreported whether the 71 
bactericidal activity of surotomycin encompasses the non-growing stationary phase C. 72 
difficile. Killing of stationary phase cells by membrane-active antibiotics has been shown 73 
to lower toxin and spore numbers in vitro, which in principle could contribute to lowering 74 
disease severity and rates of endogenous recurrence (11).  The basis for surotomycin’s 75 
potent activity against C. difficile is thought to arise from dissipation of the bacterial 76 
membrane as shown in S. aureus (19).  However, direct studies determining if 77 
surotomycin dissipates the membrane potential of C. difficile have not been reported.  78 
Herein, we characterized the mode of action of surotomycin against C. difficile, 79 
examining its bactericidal effects on logarithmic and stationary phase cells and associated 80 
cellular effects linked to dissipation of the membrane potential in C. difficile.  This study 81 
was presented in part as a poster presentation at the 54th Interscience Conference on 82 
Antimicrobial Agents and Chemotherapy (ICAAC). 83 
 84 
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MATERIALS AND METHODS 85 
Compounds, bacterial strains, and growth media. Surotomycin and daptomycin were 86 
provided by Merck and Co., Inc. All other antimicrobials were obtained from Sigma-87 
Aldrich (vancomycin, metronidazole, CCCP, ampicillin, fusidic acid, rifaximin and nisin) 88 
or Enzo Life Sciences (gatifloxacin). The C. difficile strains BAA-1875 (ribotype 078) 89 
and BAA-1803 (ribotype 027) were from the American Type Culture Collection (ATCC). 90 
Strain R20291 (ribotype 027) was kindly provided by Dr. A. L. Sonenshein, Tuft 91 
University, Boston USA. Strain IT0843 (ribotype 001) was kindly provided by Dr. Paola 92 
Mastrantonio (Istituto Superiore di Sanità, Rome, Italy). Brain Heart Infusion (BHI; from 93 
Oxoid) was used for all the experiments and was supplemented with calcium to a final 94 
concentration of 50 mg/L for all experiments with surotomycin and daptomycin. To 95 
supplement BHI to a final calcium concentration of 50 mg/L, calcium levels in 96 
manufactured lots of BHI were determined by the Laboratory Specialists, Inc., OH.  All 97 
strains were routinely grown in pre-reduced BHI media under anaerobic conditions in a 98 
Whitley A35 anaerobic workstation at 37°C. 99 
 100 
Determination of minimum inhibitory concentrations (MICs) and minimum 101 
bactericidal concentrations (MBCs). Minimum inhibitory and minimum bactericidal 102 
concentrations of compounds against C. difficile were determined as described by Wu et 103 
al. (11, 23).  MICs were performed using ~106 cfu/mL inoculum of C. difficile in 24-well 104 
microtitre plates containing 2-fold serial dilutions of compounds in a total volume of 1 105 
mL. MICs were defined as the lowest concentrations of compounds inhibiting visible 106 
growth after 24 h of incubation. MBCs were performed against both the logarithmic-107 
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phase (MBCLog) and stationary-phase (MBCSta) cells using logarithmic (OD600nm≈0.3) 108 
and 24 h old cultures, respectively. Briefly, in 24-well microtitre plates, cultures were 109 
added to 2-fold diluted compounds in a total volume of 1 mL. After 24 h of incubation, 110 
the number of viable cells was determined by plating aliquots onto pre-reduced BHI agar 111 
containing activated charcoal (10 % w/v). MBCs were defined as the lowest 112 
concentrations of compounds causing ≥3 log reduction in viable cells compared to the 113 
starting inocula. The MICs and MBCs were determined from two independent starting 114 
cultures. 115 
 116 
Time-kill kinetics, Were evaluated against both the logarithmic and stationary phase 117 
cultures as described by Wu et al. (11, 23). Logarithmic (OD600nm ≈0.3) and stationary-118 
phase cultures were exposed to 1, 4 and 16× the MIC of compounds.  Samples (100 μL) 119 
were taken at time 0, 1, 2, 4, 6 and 24 h after the addition of compounds and viable cell 120 
counts were determined on BHI agar plates containing activated charcoal (10 % w/v). 121 
Bacterial counts were enumerated after 24 h of incubation.  This assay were determined 122 
from two independent starting cultures. 123 
 124 
Effects on macromolecular biosynthesis. Logarithmic cultures of R20291 and BAA-125 
1875 were grown to early logarithmic-phase (OD600nm ≈0.3) under anaerobic conditions 126 
and aliquoted for subsequent analysis. To analyze the DNA, RNA, protein and cell wall 127 
synthesis inhibition; 3H-Thymidine (2 μCi/mL), 3H-Uridine (2 μCi/mL), 3H-Threonine (2 128 
μCi/mL) and 3H- N-acetyl-Glucosamine (2 μCi/mL) were used respectively. 129 
Radiolabelled precursors were added 5 min before the addition of compounds at either 130 
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inhibitory (1×MIC) and bactericidal (16×MIC) concentrations. Gatifloxacin, rifaximin, 131 
fusidic acid and ampicillin were used as controls for DNA, RNA, Protein and cell wall 132 
synthesis inhibition, respectively. Against BAA-1875 strain, gatifloxacin, rifaximin, 133 
fusidic acid, and ampicillin concentrations at 16×MIC, were 64 μg/mL, 0.96 μg/mL, 2 134 
μg/mL, and 8 μg/mL, respectively.  Against R20291, the concentrations at 16×MIC were 135 
512 μg/mL, 2 μg/mL, 2 μg/mL, and 16 μg/mL, for the respective control drugs.  Samples 136 
(500 μL) were taken at specific time points (30, 60 and 120 min), spun down, and the cell 137 
pellet collected and incubated on ice with 10% w/v ice-cold trichloroacetic acid (TCA) 138 
for 30 min. Samples were then ﬁltered through Whatman GF/C ﬁlters, washed twice with 139 
5% w/v TCA and 95% ethanol. Filters were dried and scintillation counting performed. 140 
 141 
Determination of the membrane potential and permeability using FACS. To assess 142 
the effects of compounds on the membrane potential and permeability of C. difficile, we 143 
adopted a fluorocytometric method relying on the use of DiBAC4(3) to assess the 144 
membrane potential and propidium iodide (PI) to assess membrane permeability. This 145 
method was based on that reported by Nuding et al. (24) for anaerobic bacteria; 146 
Diethyloxacarbocyanine iodide DiOC2(3) was found to be inconsistent (data not shown). 147 
Strains R20291 and BAA-1875 were used, and were exposed to different concentrations 148 
of compounds as: 1, 4 and 16× the MIC of compounds. Briefly, cultures were grown 149 
anaerobically to an OD600nm ≈0.2 and 10 mL aliquots added to 20 mL serum vials.  150 
Compounds were subsequently added and the vials crimped sealed with silicone bungs 151 
and removed from the anaerobic chamber. After 10 min of adding compound, DiBAC4(3) 152 
was added via a 23G syringe needle to a final concentration of 5 μM. After an overall 30 153 
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min of exposing cells to compounds, at room temperature, fluorocytometric analysis was 154 
performed using BD LSR II flow cytometer.  DiBAC4(3) was excited using the 488-nm 155 
excitation laser and its fluorescence emission detected using FITC filters.  As a positive 156 
carbonyl cyanide m-chlorophenyl hydrazone (CCCP; Sigma-Aldrich), which completely 157 
dissipates the membrane potential was used; vancomycin was used as a negative control; 158 
a minimum of three independent cultures was evaluated.  159 
Membrane permeability assays were similarly performed using the protocol 160 
described above, except that the membrane impermanent dye PI was added to a final 161 
concentration of 5 μM instead of DiBAC4(3).  After 30 min samples were analyzed in the 162 
BD LSR II flow cytometer, with excitation at 488-nm and emission collected using the 163 
PI-A filters.  Nisin was used as a positive control for membrane damage and vancomycin 164 
as a negative control. Daptomycin was also included as a control in these experiments.  165 
Resazurin (0.001 gm/L) and sodium thioglycollate (0.5 gm/L) were added to the media to 166 
act as an indicator of oxygenation and an oxygen scavenger, respectively. Histogram 167 
plots of number of events against fluorescence of the population were comparatively 168 
analyzed using FlowJo X 10.0.7. 169 
 170 
RESULTS 171 
Surotomycin is bactericidal against both the logarithmic and stationary-phase C. 172 
difficile. As shown in Table 1, surotomycin MICs against test strains ranged from 0.125 173 
to 1 µg/mL. The concentration of surotomycin required for bactericidal activities against 174 
logarithmic and stationary phase cultures were similar and was 8-128 fold above the 175 
MICs (Table 1), which corresponds to 2 to 16 µg/mL. As expected the control 176 
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metronidazole was also bactericidal, killing both culture types at concentrations between 177 
2 to 16 µg/mL, whereas vancomycin was bacteriostatic and was completely inactive 178 
against stationary-phase C. difficile.  179 
 180 
Surotomycin kills C. difficile in a concentration-dependent manner. Time kill kinetics 181 
were subsequently performed to determine how rapidly surotomycin killed both 182 
logarithmic and stationary phase cells.  These assays revealed that surotomycin exhibited 183 
a concentration dependent mode of killing against both the logarithmic- and stationary-184 
phase cultures of C. difficile. Against logarithmic BAA-1875, at 16×MIC (4 µg/mL), 185 
surotomycin killed more than 99% of cells in 6 h, whereas 24 h was required to achieve a 186 
similar reduction in culture viability, against stationary-phase cells (Figure 1). A similar 187 
pattern of killing was observed against R20291, although, this strain seemed more 188 
sensitive at 4×MIC of surotomycin, since a 99% reduction in viable numbers was 189 
observed after 24 h against logarithmic-phase cultures (Figure 2). This suggests that 190 
against R20291 in larger culture volume (10 mL) the MBC is 4 μg/mL, which differs by 191 
4-fold from that obtained in 1 mL volumes for MBC determinations. Metronidazole was 192 
also found to display concentration dependent killing (against both logarithmic and 193 
stationary-phase cells), causing a ≥99% reduction of viable cells at 16×MIC after 24 h; 194 
whereas vancomycin demonstrated bacteriostatic effect and was completely inactive 195 
against stationary-phase cultures.  These observations broadly support the above findings 196 
of the MBCs data. 197 
 198 
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Surotomycin dissipates membrane potential without pore formation. In order to 199 
examine whether surotomycin dissipates the membrane potential of C. difficile, we 200 
adopted the fluorescent probe DiBAC4(3).  The fluorescence of DiBAC4(3) changes with 201 
the membrane potential status of cells, with depolarized cells demonstrating enhanced 202 
fluorescence, due to DiBAC4(3) entering depolarized membranes and binding to lipid-203 
rich intracellular components, thereby exhibiting increased green fluorescence (24). 204 
When C. difficile cultures of R20291 and BAA-1875 were treated with surotomycin or 205 
daptomycin, increases in florescence were only observed 16× their MICs, compared to 206 
the untreated cultures (Figure 3). These concentrations were bactericidal for both agents.  207 
No changes in the fluorescence of cells were observed at lower concentrations of 208 
surotomycin or daptomycin (i.e. 1 and 4×MIC). As expected, the negative control 209 
vancomycin that inhibits peptidoglycan biosynthesis did not alter the membrane 210 
potential, while CCCP that acts as a proton ionophore and disrupts the bacterial 211 
membrane potential was shown to increase the fluorescence of R20291 and BAA-1875. 212 
At the 30 min of treatment, dissipation of the membrane potential by surotomycin and 213 
daptomycin at 16× their MICs did not result in membrane pore formation, as cells did not 214 
show an increase in propidium iodide fluorescence compared to the untreated control and 215 
vancomycin-treated cultures. In contrast, the pore-forming agent nisin caused membrane 216 
pore formation, which was evident by an increase in the red fluorescence of cells (Figure 217 
3). 218 
As the above observations are based on 30 min incubation periods, we extended 219 
out incubation times.  Incubation of cultures with 1 and 4×MIC of surotomycin or 220 
daptomycin for up to 2 h did not lead to an observable difference in the membrane 221 
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potential status of cells compared to untreated controls (data not shown).  Similarly, 222 
continued exposure to 16×MIC of these drugs did not produce further, measurable 223 
increases in the dissipation of the membrane potential; extended incubation times at 1, 4, 224 
and 16×MIC did not lead to increases in the permeability of cultures to propidium iodide 225 
(data not shown). 226 
 227 
Surotomycin inhibits multiple macromolecular biosynthetic processes. Exposure of 228 
R20291 and BAA-1875 to inhibitory (MIC) and bactericidal (16×MIC) concentrations of 229 
surotomycin resulted in the simultaneous inhibition of DNA, RNA, Protein and Cell Wall 230 
(Figure 4).  While it is expected that at the bactericidal concentration, all 231 
macromolecular processes would be affected in dying cells, these processes were also 232 
affected in cells exposed to inhibitory concentrations.  This is consistent with the 233 
membrane being the primary target for surotomycin action, thereby imposing multiple 234 
cellular effects on processes that require membrane homeostasis (25).  235 
DISCUSSION 236 
Recent studies established that the membrane potential of C. difficile is critical to the 237 
survival of logarithmic and stationary phase cells, making the clostridial membrane an 238 
attractive target for agents to treat CDI (11).  Dissipation of the membrane potential, 239 
resulting in loss of viability in both growing and non-growing cell types has direct 240 
relevance to C. difficile pathogenesis, as this organism produces its toxins and spores in 241 
the late-logarithmic and stationary phases of growth (22). The cyclic lipopeptide drug 242 
surotomycin represents the leading example of a membrane-active antibiotic for treating 243 
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CDI.  In studies herein we validated that surotomycin dissipates the membrane potential 244 
of C. difficile and this was not associated with the formation of pores at bactericidal 245 
concentrations in two test strains. This observation is consistent with a prior report by 246 
Mascio et al. (19) where surotomycin dissipated the membrane potential of S. aureus 247 
without causing pore formation. Dissipation of the membrane potential of C. difficile was 248 
evaluated using the fluoroprobe DiBAC4(3) that other studies have adopted to measure 249 
the membrane potential in anaerobes and as it appears more reliable than DiOC for 250 
anaerobes (24). However, measurable disruptions of the membrane potential in C. 251 
difficile were only observed at bactericidal concentrations.  This might reflect that the 252 
magnitude of the membrane potential in clostridia is low (26).  Hence the marginal 253 
lowering of the membrane potential of C. difficile upon exposure to inhibitory 254 
concentrations of drug may be challenging to measure using DiBAC4(3) and other 255 
techniques may be required for lower concentrations.    256 
The action of surotomycin against various strains of C. difficile resulted in 257 
bactericidal activities against logarithmic and stationary phase cultures and imposed 258 
multiple cellular effects as evident by widespread disruption of macromolecular 259 
processes.  In contrast, the cell wall synthesis inhibitor vancomycin was poorly active or 260 
bacteriostatic against logarithmic cells and inactive against stationary phase cultures.  261 
Metronidazole did reduce the viability of both cell types, but only low concentrations of 262 
drug occur in the gastrointestinal tract as the drug is almost completely absorbed 263 
following oral administration (27).   264 
 The concentration of surotomycin that was required to inactivate both logarithmic 265 
and stationary phase cultures was typically 2-16 μg/mL.  These levels are well within the 266 
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local concentrations of surotomycin (>1,000 μg/g) that is present in the colon of patients 267 
following oral administration (data on file at Merck and Co., Inc. Kenilworth, NJ, USA).  268 
It is therefore plausible that in the colon surotomycin is bactericidal against both 269 
logarithmic and stationary phase cells. This property could reduce both toxin and spore 270 
production in vegetative populations, as recently reported in the in vitro human gut model 271 
(28).  In Phase II clinical trials, lower rates of recurrence was associated with 272 
surotomycin treatment compared to oral vancomycin; as 27.9% and 17.2% for 273 
surotomycin at 125 mg and 250 mg twice daily, respectively; while 35.6% for 274 
vancomycin given as 125 mg four times per day (29).  From a microbiological 275 
perspective, it is tempting to speculate that surotomycin’s bactericidal activity and 276 
narrower spectrum than vancomycin contributes to reducing recurrence.  However, the in 277 
vitro findings of this study do not provide a direct explanation for the superiority of 278 
surotomycin compared to vancomycin in reducing recurrence.   279 
  The present study reported herein provides a solid framework from which to 280 
rationalize several recent findings on the in vitro activities against C. difficile.  Indeed, 281 
reported observations that surotomycin is bactericidal against logarithmic cultures with a 282 
long post-antibiotic effect, reduces toxin and spore production and has a low propensity 283 
to select for de novo resistance in C. difficile (19, 28), can be rationalized as being 284 
consistent with membrane as the biological target. 285 
   286 
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TABLES AND FIGURES 386 
 387 
Table 1: In vitro activities of surotomycin and other first-line drugs for the treatment of 388 
CDI 389 
 *Activity μg/mL 
 BAA-1875 (078) R20291 (027) IT0843 (001) 
 MIC MBCLOG MBCSTA MIC MBCLOG MBCSTA MIC MBCLOG MBCSTA 
Surotomycin 0.25 4 2 1 8 16 0.125 8 16 
Metronidazole 0.5 2 8 0.5 8 16 0.25 1 16 
Vancomycin 0.5 >128 >128 2 >128 >128 2 >128 >128
 390 
*MBCLOG, minimum bactericidal concentration against logarithmic cells; MBCSTA 391 
minimum bactericidal concentration against stationary phase cells. 392 
 393 
 394 
 395 
 396 
 397 
 398 
 399 
 400 
 401 
 402 
 403 
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Figure 1: Time-kill kinetics of antibiotics against logarithmic-phase (left) and stationary-404 
phase (right) BAA-1875 cultures. Various concentrations of SUR = surotomycin; MTZ = 405 
metronidazole; and VAN = vancomycin are shown in the legend.  406 
 407 
Figure 2: Time-kill kinetics of antibiotics against logarithmic-phase (left) and stationary-408 
phase (right) R20291 cultures. Various concentrations of SUR = surotomycin; MTZ = 409 
metronidazole; and VAN = vancomycin are shown in the legend.  410 
 411 
Figure 3: Dissipation of the membrane potential and effects on membrane permeability 412 
of C. difficile, shown as histogram half overlays. Representative data from three 413 
independent cultures of BAA-1875 is shown, following exposure to drugs at 16×MIC. A. 414 
CCCP was used as a control for dissipation of membrane potential and in B nisin is used 415 
as a pore forming control; vancomycin is a negative control. CON = Control, SUR = 416 
Surotomycin (4 μg/mL), DAP = Daptomycin (16 μg/mL), CCCP = Carbonyl cyanide m-417 
chlorophenyl hydrazine (2 μg/mL), NSN = Nisin (8 μg/mL), VAN = Vancomycin (8 418 
μg/mL). Filters for FITC = Fluorescein Isothiocyanate, PI = Propidium Iodide. 419 
 420 
Figure 4: Effects of inhibitory and bactericidal concentrations of surotomycin (SUR) on 421 
macromolecular biosynthesis in C. difficile. In A, effects against BAA-1875 is shown for 422 
SUR (0.25 and 4 μg/mL); whereas in B effects against R20291 is shown for SUR (1 and 423 
16 μg/mL). Control drugs are also shown in both A (Gatifloxacin = 64 μg/mL; Rifaximin 424 
= 0.96 μg/mL; Fusidic Acid = 2 μg/mL; Ampicillin = 8 μg/mL) and B (Gatifloxacin = 425 
512 μg/mL; Rifaximin = 2 μg/mL; Fusidic Acid = 2 μg/mL; Ampicillin = 16 μg/mL).  426 
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